ZA201203330B - Melanocortin-1 receptor-specific cyclic peptides - Google Patents
Melanocortin-1 receptor-specific cyclic peptidesInfo
- Publication number
- ZA201203330B ZA201203330B ZA2012/03330A ZA201203330A ZA201203330B ZA 201203330 B ZA201203330 B ZA 201203330B ZA 2012/03330 A ZA2012/03330 A ZA 2012/03330A ZA 201203330 A ZA201203330 A ZA 201203330A ZA 201203330 B ZA201203330 B ZA 201203330B
- Authority
- ZA
- South Africa
- Prior art keywords
- melanocortin
- receptor
- cyclic peptides
- specific cyclic
- specific
- Prior art date
Links
- 102000001189 Cyclic Peptides Human genes 0.000 title 1
- 108010069514 Cyclic Peptides Proteins 0.000 title 1
- 102000008314 Type 1 Melanocortin Receptor Human genes 0.000 title 1
- 108010021428 Type 1 Melanocortin Receptor Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C07K14/68—Melanocyte-stimulating hormone [MSH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26349009P | 2009-11-23 | 2009-11-23 | |
| PCT/US2010/057699 WO2011063366A1 (en) | 2009-11-23 | 2010-11-23 | Melanocortin-1 receptor-specific cyclic peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201203330B true ZA201203330B (en) | 2013-07-31 |
Family
ID=44060071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2012/03330A ZA201203330B (en) | 2009-11-23 | 2012-05-08 | Melanocortin-1 receptor-specific cyclic peptides |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US8492517B2 (enExample) |
| EP (1) | EP2504352B1 (enExample) |
| JP (1) | JP5999702B2 (enExample) |
| KR (1) | KR101921761B1 (enExample) |
| CN (1) | CN102725305B (enExample) |
| AU (2) | AU2010321738B2 (enExample) |
| BR (1) | BR112012011787B1 (enExample) |
| CA (1) | CA2781402C (enExample) |
| EA (1) | EA021897B1 (enExample) |
| IL (1) | IL219947A (enExample) |
| MX (1) | MX2012005862A (enExample) |
| NZ (1) | NZ599774A (enExample) |
| WO (1) | WO2011063366A1 (enExample) |
| ZA (1) | ZA201203330B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2781402C (en) | 2009-11-23 | 2017-03-21 | Palatin Technologies, Inc. | Melanocortin-1 receptor-specific cyclic peptides |
| JP2013511554A (ja) | 2009-11-23 | 2013-04-04 | パラティン テクノロジーズ，インコーポレイテッド | メラノコルチン−１受容体特異的線状ペプチド |
| EP2814501A4 (en) | 2012-03-13 | 2016-03-02 | Tensive Controls Inc | MELANOCORTINANALOGA WITH INCREASED EFFECTIVENESS AND TRANSPORTATION OF THEREOF |
| MX366171B (es) * | 2012-11-21 | 2019-07-01 | Univ Cincinnati | Composiciones farmaceuticas y metodos terapeuticos de uso que comprenden agonistas selectivos del receptor de melanocortina. |
| WO2015063102A1 (en) | 2013-10-28 | 2015-05-07 | Clinuvel Ag | Alpha-msh analogues for use in bullous disease |
| WO2015063099A1 (en) | 2013-10-28 | 2015-05-07 | Clinuvel Ag | Alpha-msh analogues for use in the treatment of hailey-hailey disease |
| WO2015067503A1 (en) | 2013-11-07 | 2015-05-14 | Clinuvel Ag | Alpha-msh analogues for use in the treatment of psoriasis |
| US20160354437A1 (en) | 2014-02-13 | 2016-12-08 | Northwestern University | Compositions and methods for modulation of immune response |
| WO2016066702A1 (en) | 2014-10-28 | 2016-05-06 | Clinuvel Ag | Inflammatory disease |
| WO2016066700A1 (en) | 2014-10-28 | 2016-05-06 | Clinuvel Ag | New indication for alpha-msh analogues |
| NZ731185A (en) | 2014-10-29 | 2024-03-22 | Bicyclerd Ltd | Bicyclic peptide ligands specific for mt1-mmp |
| WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
| US10729669B2 (en) | 2015-07-28 | 2020-08-04 | University Of Iowa Research Foundation | Compositions and methods for treating cancer |
| AU2017281940C1 (en) | 2016-06-24 | 2024-11-07 | University Of Iowa Research Foundation | Compositions and methods of treating melanoma |
| WO2018065345A1 (en) * | 2016-10-04 | 2018-04-12 | Dsm Ip Assets B.V. | Melanocortin-1-receptor agonists |
| CA3050630A1 (en) | 2017-02-01 | 2018-08-09 | Clinuvel Pharmaceuticals Ltd | Alpha-msh analogues used in the treatment of xeroderma pigmentosum |
| CN118772242A (zh) | 2017-08-04 | 2024-10-15 | 拜斯科技术开发有限公司 | Cd137特异性的双环肽配体 |
| BR112020014576A2 (pt) | 2018-02-23 | 2020-12-08 | Bicycletx Limited | Ligantes peptídicos bicíclicos multiméricos |
| JP2021523931A (ja) * | 2018-03-23 | 2021-09-09 | パラティン テクノロジーズ， インコーポレイテッド | メラノコルチン受容体特異的ペプチド製剤及び消化管特異的送達方法 |
| GB201810316D0 (en) * | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| GB201810325D0 (en) * | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to PSMA |
| IL279489B2 (en) | 2018-06-22 | 2025-10-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate |
| GB201810327D0 (en) * | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to IL-17 |
| CN113166204B (zh) | 2018-11-27 | 2025-01-28 | 诺华股份有限公司 | 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状肽 |
| UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| EP3897849A1 (en) | 2018-12-21 | 2021-10-27 | BicycleTx Limited | Bicyclic peptide ligands specific for pd-l1 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| US11529335B2 (en) | 2020-07-31 | 2022-12-20 | University Of Iowa Research Foundation | Compositions and methods for treating cancer |
| WO2023091689A1 (en) | 2021-11-19 | 2023-05-25 | University Of Iowa Research Foundation | Combined use of mcr1-directed radiotherapy and immune checkpoint inhibition in the treatment of melanoma |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5683981A (en) | 1987-05-22 | 1997-11-04 | Competitive Technologies, Inc. | Cyclic bridged analogs of α-MSH and methods thereof |
| ATE109793T1 (de) | 1987-05-22 | 1994-08-15 | University Patents Inc | Lineare und zyklische analoge von alpha-msh- fragmenten mit ausserordentlicher wirkung. |
| US5674839A (en) | 1987-05-22 | 1997-10-07 | Competitive Technologies, Inc. | Cyclic analogs of alpha-MSH fragments |
| US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
| US6100048A (en) | 1992-04-10 | 2000-08-08 | Oregon Health Sciences University | Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals |
| DE69429768T2 (de) | 1993-04-05 | 2002-09-19 | Competitive Technologies, Inc. | Diagnose und behandlung von erektilen funktionsstörungen |
| US5731408A (en) | 1995-04-10 | 1998-03-24 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Peptides having potent antagonist and agonist bioactivities at melanocortin receptors |
| US6054556A (en) | 1995-04-10 | 2000-04-25 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Melanocortin receptor antagonists and agonists |
| US7396814B2 (en) | 1995-06-07 | 2008-07-08 | Palatin Technologies, Inc. | Metallopeptide compositions for treatment of sexual dysfunction |
| CA2158425C (en) | 1995-09-15 | 2003-01-28 | Mac E. Hadley | Diagnostic and treatment of erectile dysfunction |
| IL118003A0 (en) | 1996-04-23 | 1996-08-04 | Yeda Res & Dev | Novel vip fragments and pharmaceutical compositions comprising them |
| JP2001506996A (ja) | 1996-12-17 | 2001-05-29 | クアドラント ホールディングス ケンブリッジ リミテッド | メラノコルチン受容体３、４又は５の特異結合のためのメラノコルチン誘導体 |
| US6350430B1 (en) | 1997-10-27 | 2002-02-26 | Lion Bioscience Science Ag | Melanocortin receptor ligands and methods of using same |
| US20020099003A1 (en) | 1997-10-28 | 2002-07-25 | Wilson Leland F. | Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof |
| GB9808229D0 (en) | 1998-04-17 | 1998-06-17 | Quadrant Holdings Cambridge | Melanocortin receptor ligands |
| US6284735B1 (en) | 1998-04-28 | 2001-09-04 | Lion Bioscience Ag | HP-3228 and related peptides to treat sexual dysfunction |
| US6534503B1 (en) | 1998-04-28 | 2003-03-18 | Lion Bioscience Ag | Melanocortin receptor-3 ligands to treat sexual dysfunction |
| SE9801571D0 (sv) | 1998-05-05 | 1998-05-05 | Wapharm Ab | Melanokortin-1-receptorselektiva föreningar |
| SE9804614A0 (en) | 1998-07-06 | 2000-01-07 | A+ Science Invest Ab | New peptides and use thereof |
| GB9816234D0 (en) | 1998-07-24 | 1998-09-23 | William Harvey Research Limite | Compounds for use in the treatment of inflammation |
| GB9827500D0 (en) | 1998-12-14 | 1999-02-10 | Wapharm Ab | Compounds for control of eating, growth and body weight |
| ES2260948T3 (es) | 1998-12-23 | 2006-11-01 | MERCK & CO., INC. | Moleculas de adn que codifican variantes ajustadas de la proteina del receptor de la melanocortina-1. |
| US6887846B2 (en) | 1999-03-24 | 2005-05-03 | Zengen, Inc. | Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone |
| NZ514141A (en) | 1999-03-29 | 2004-01-30 | Procter & Gamble | Melanocortin receptor ligands |
| HUP0201696A3 (en) * | 1999-06-25 | 2002-10-28 | Sod Conseils Rech Applic | Cyclic peptides, pharmaceutical compositions comprising thereof and their use |
| US7176279B2 (en) * | 2000-06-28 | 2007-02-13 | Palatin Technologies, Inc. | Cyclic peptide compositions and methods for treatment of sexual dysfunction |
| US6579968B1 (en) | 1999-06-29 | 2003-06-17 | Palatin Technologies, Inc. | Compositions and methods for treatment of sexual dysfunction |
| US7235625B2 (en) * | 1999-06-29 | 2007-06-26 | Palatin Technologies, Inc. | Multiple agent therapy for sexual dysfunction |
| US6699873B1 (en) | 1999-08-04 | 2004-03-02 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
| US7049398B1 (en) | 1999-08-12 | 2006-05-23 | Palatin Technologies, Inc. | Melanocortin metallopeptide constructs, combinatorial libraries and applications |
| WO2001030808A1 (en) | 1999-10-27 | 2001-05-03 | The Regents Of The University Of California | Methods and compounds for modulating melanocortin receptor-ligand binding |
| US20030064921A1 (en) | 1999-10-27 | 2003-04-03 | The Regents Of The University Of California | Methods and compounds for modulating melanocortin receptor ligand binding and activity |
| EP1251865A1 (en) | 2000-01-18 | 2002-10-30 | Merck & Co., Inc. | Cyclic peptides as potent and selective melanocortin-4 receptor antagonists |
| US6600015B2 (en) | 2000-04-04 | 2003-07-29 | Hoffmann-La Roche Inc. | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity |
| WO2001085930A2 (en) | 2000-05-09 | 2001-11-15 | The Regents Of The University Of California | Methods and compounds for modulating melanocortin receptor ligand binding and activity |
| GB0012370D0 (en) | 2000-05-22 | 2000-07-12 | Quadrant Holdings Cambridge | Peptoids |
| SI1315750T1 (sl) | 2000-08-30 | 2007-06-30 | Hoffmann La Roche | Cikliäśni peptidi kot agonisti za receptorje melanokortina-4 |
| EP1409540A2 (en) | 2000-09-27 | 2004-04-21 | The Procter & Gamble Company | Melanocortin receptor ligands |
| US20030113263A1 (en) | 2001-02-13 | 2003-06-19 | Oregon Health And Sciences University, A Non-Profit Organization | Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia |
| ITMI20011057A1 (it) | 2001-05-22 | 2002-11-22 | Bracco Imaging Spa | Preparazione ed uso di peptidi ciclici e ramificati e loro deriati marcati come agenti terapeutici agonisti o antagonisti della colecistochi |
| EP1441750A4 (en) | 2001-07-11 | 2006-10-18 | Palatin Technologies Inc | LINEAR AND CYCLIC PEPTIDES SPECIFIC TO THE MELANOCORTIN RECEPTOR |
| US7342089B2 (en) * | 2001-07-11 | 2008-03-11 | Palatin Technologies, Inc. | Cyclic peptides for treatment for cachexia |
| US7345144B2 (en) | 2001-07-11 | 2008-03-18 | Palatin Technologies, Inc. | Cyclic peptides for treatment of cachexia |
| WO2003006604A2 (en) | 2001-07-12 | 2003-01-23 | Merck & Co., Inc. | Cyclic peptides as potent and selective melanocortin-4 receptor agonists |
| CA2462200A1 (en) * | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
| FR2835528B1 (fr) | 2002-02-01 | 2004-03-12 | Inst Europ Biolog Cellulaire | Nouveaux derives peptidiques, leur preparation et leur application therapeutique et cosmetique |
| US20030186249A1 (en) | 2002-04-01 | 2003-10-02 | Zairen Sun | Human TARPP genes and polypeptides |
| US7034004B2 (en) | 2002-05-07 | 2006-04-25 | University Of Florida | Peptides and methods for the control of obesity |
| BR0305628A (pt) | 2002-07-09 | 2004-09-08 | Palatin Technologies Inc | Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso |
| WO2004046166A2 (en) | 2002-11-14 | 2004-06-03 | Zengen, Inc. | Modified alpha-msh peptides and derivatives thereof |
| US7135548B2 (en) | 2002-11-14 | 2006-11-14 | Zengen, Inc. | Modified α-MSH peptides and derivatives thereof |
| AU2004235872A1 (en) * | 2003-05-09 | 2004-11-18 | Novo Nordisk A/S | Peptides for use in treating obesity |
| KR20060026011A (ko) * | 2003-05-09 | 2006-03-22 | 노보 노르디스크 에이/에스 | 비만 치료용 펩티드 |
| AU2004251616A1 (en) | 2003-06-19 | 2005-01-06 | Eli Lilly And Company | Melanocortin receptor 4(MC4) agonists and their uses |
| WO2005000338A1 (en) | 2003-06-19 | 2005-01-06 | Eli Lilly And Company | Uses of melanocortin-3 receptor (mc3r) agonist peptides |
| US7084111B2 (en) | 2003-06-23 | 2006-08-01 | University Of Florida Research Foundation, Inc. | Melanocortin receptor templates, peptides, and use thereof |
| US20050026948A1 (en) | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
| DE602004006279T2 (de) | 2003-08-20 | 2007-12-27 | Eli Lilly And Co., Indianapolis | Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagonartigen peptid (glp)-1-verbindung oder eines melanocortin-4-rezeptor-(mc4-)agonistschen peptids |
| CA2539596A1 (en) | 2003-09-30 | 2005-04-07 | Kilian Waldemar Conde-Frieboes | Melanocortin receptor agonists |
| KR100661118B1 (ko) | 2003-11-12 | 2006-12-26 | 주식회사 엘지생명과학 | 멜라노코틴 수용체의 항진제 |
| JP5230941B2 (ja) | 2003-11-24 | 2013-07-10 | クリヌベール、ファーマスーティカルズ、リミテッド | Ｍｃ１ｒ変異対立遺伝子を有するヒトにおいてメラニン形成を誘導する方法 |
| EP1694348A4 (en) | 2003-12-10 | 2009-07-01 | Merck & Co Inc | INHIBITION OF VOLUNTARY ETHANOL CONSUMPTION WITH SELECTIVE MELANOCORTIN-4-RECEPTOR AGONISTS |
| WO2005090388A1 (en) * | 2004-03-19 | 2005-09-29 | The University Of Queensland | Alpha helical mimics, their uses and methods for their production |
| WO2005102377A1 (en) | 2004-03-29 | 2005-11-03 | Eli Lilly And Company | Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion |
| CN1563076A (zh) | 2004-04-02 | 2005-01-12 | 西南生物工程产业化中试基地有限公司 | 一种用于治疗性功能障碍的α－MSH类似物及制备方法 |
| US7442693B2 (en) | 2004-05-28 | 2008-10-28 | Smithkline Beecham Corporation | Diazepine compounds as ligands of the melanocortin 1 and/or 4 receptors |
| NZ582130A (en) | 2004-08-04 | 2011-11-25 | Clinuvel Pharmaceuticals Ltd | Methods of inducing melanogenesis in a subject |
| TW200626611A (en) | 2004-09-20 | 2006-08-01 | Lonza Ag | Peptide cyclisation |
| JP5449673B2 (ja) | 2004-10-08 | 2014-03-19 | クリヌベール、ファーマスーティカルズ、リミテッド | 対象者におけるメラニン形成を誘導するための組成物および方法 |
| JP2008517605A (ja) | 2004-10-25 | 2008-05-29 | セントカー・インコーポレーテツド | メラノコルチン受容体結合性ミメティボディ、組成物、方法および用途 |
| WO2006048449A2 (en) | 2004-11-04 | 2006-05-11 | Novo Nordisk A/S | Mc4r selective peptides and their use in the treatment of obesity |
| JP2008519009A (ja) | 2004-11-04 | 2008-06-05 | ノボ ノルディスク アクティーゼルスカブ | 肥満症の治療に使用するためのペプチド |
| JP2008519007A (ja) | 2004-11-04 | 2008-06-05 | ノボ ノルディスク アクティーゼルスカブ | 肥満症の治療に使用するためのペプチド |
| JP2008519008A (ja) | 2004-11-04 | 2008-06-05 | ノボ ノルディスク アクティーゼルスカブ | 肥満症の治療に使用するためのペプチド |
| WO2006060873A1 (en) | 2004-12-09 | 2006-06-15 | Prince Henry's Institute Of Medical Research | Method for restoring reproductive function |
| WO2006073771A2 (en) | 2005-01-05 | 2006-07-13 | Eli Lilly And Company | Polyethylene glycol linked mc4r or mc3r agonist peptides |
| US7563781B2 (en) | 2005-01-14 | 2009-07-21 | Janssen Pharmaceutica Nv | Triazolopyrimidine derivatives |
| WO2006097526A1 (en) | 2005-03-17 | 2006-09-21 | Novo Nordisk A/S | Compounds for use in the treatment of obesity |
| CA2609951A1 (en) | 2005-05-31 | 2006-12-07 | Yissum Research Development Company Of The Hebrew University Of Jerusale M | Backbone cyclized melanocortin stimulating hormone (.alpha.s) analogs |
| CA2614678A1 (en) | 2005-07-08 | 2007-01-18 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R | Ligands of melanocortin receptors |
| ES2663916T3 (es) | 2005-07-08 | 2018-04-17 | Ipsen Pharma | Ligandos de los receptores de la melanocortina |
| CN1709906A (zh) | 2005-07-15 | 2005-12-21 | 中国科学技术大学 | α－促黑激素的环状类似肽及其应用 |
| WO2007009894A2 (en) | 2005-07-18 | 2007-01-25 | Novo Nordisk A/S | Peptides for use in the treatment of obesity |
| EP2272866B1 (en) | 2005-08-26 | 2018-09-19 | AbbVie Inc. | Therapeutically active alpha-msh analogues |
| WO2007027574A2 (en) | 2005-08-29 | 2007-03-08 | Palatin Technologies, Inc. | Cyclic peptide isolation by spray drying |
| WO2007035474A2 (en) | 2005-09-15 | 2007-03-29 | Novomed Technologies, Inc. (Shanghai) | Transdermal delivery peptides and method of use thereof |
| US8114844B2 (en) * | 2006-03-30 | 2012-02-14 | Palatin Technologies, Inc. | Linear and cyclic melanocortin receptor-specific peptidomimetics |
| AU2007291943B2 (en) * | 2006-08-28 | 2013-11-14 | Clinuvel Pharmaceuticals Limited | Method for reducing incidence or rate of development of skin cancers and related conditions |
| JP5424887B2 (ja) | 2006-11-08 | 2014-02-26 | チョンシー ユー | ペプチド及び関連化合物の経皮送達システム |
| US7879894B2 (en) * | 2006-11-28 | 2011-02-01 | Warsaw Orthopedic, Inc. | Use of anti-cytokine agents for treating carpal and tarsal tunnel syndrome |
| EP2104684A1 (en) | 2007-01-18 | 2009-09-30 | Novo Nordisk A/S | Peptides for use in the treatment of obesity |
| EP2101822A2 (en) | 2007-01-18 | 2009-09-23 | Novo Nordisk A/S | Use of peptides in combination with surgical intervention for the treatment of obesity |
| EP2106405A2 (en) | 2007-01-18 | 2009-10-07 | Novo Nordisk A/S | Peptides for use in the treatment of obesity |
| US20100056433A1 (en) | 2007-01-18 | 2010-03-04 | Novo Nordisk A/S | Novel Peptides for Use in the Treatment of Obesity |
| JP2010516654A (ja) | 2007-01-18 | 2010-05-20 | ノボ・ノルデイスク・エー／エス | 肥満の治療に使用される新規ペプチド |
| RU2422439C2 (ru) | 2007-03-16 | 2011-06-27 | Пфайзер Лимитед | Гидрохлоридная соль 5-[3-(3-гидроксифенокси)азетидин-1-ил]-5-метил-2,2-дифенилгексанамида |
| FR2914646A1 (fr) | 2007-04-04 | 2008-10-10 | Neorphys Soc Par Actions Simpl | Analogues peptidiques des recepteurs des melanocortines |
| US20100173834A1 (en) * | 2007-06-15 | 2010-07-08 | Zheng Xin Dong | Cyclic peptide melanocortin receptor ligands |
| JP2010539182A (ja) | 2007-09-12 | 2010-12-16 | グラクソ グループ リミテッド | 治療剤の新規組み合わせ |
| CA2704651C (en) | 2007-11-05 | 2017-03-07 | Ipsen Pharma S.A.S. | Use of melanocortins to treat insulin sensitivity |
| UY31877A (es) | 2008-06-09 | 2010-01-29 | Palatin Technologies Inc | Péptidos específicos de los receptores de melanocortina para el tratamiento de la obesidad / 669 |
| AU2009257631B2 (en) * | 2008-06-09 | 2014-07-24 | Palatin Technologies, Inc. | Melanocortin receptor-specific peptides for treatment of sexual dysfunction |
| EP2440227B1 (en) * | 2009-06-08 | 2017-10-18 | Palatin Technologies, Inc. | Melanocortin receptor-specific peptides |
| WO2010144341A2 (en) | 2009-06-08 | 2010-12-16 | Palatin Technologies, Inc. | Lactam-bridged melanocortin receptor-specific peptides |
| UY32690A (es) | 2009-06-08 | 2011-01-31 | Astrazeneca Ab | Péptidos específicos para receptores de melanocortina |
| CA2781402C (en) * | 2009-11-23 | 2017-03-21 | Palatin Technologies, Inc. | Melanocortin-1 receptor-specific cyclic peptides |
| JP2013511554A (ja) * | 2009-11-23 | 2013-04-04 | パラティン テクノロジーズ，インコーポレイテッド | メラノコルチン−１受容体特異的線状ペプチド |
-
2010
- 2010-11-23 CA CA2781402A patent/CA2781402C/en active Active
- 2010-11-23 EA EA201290296A patent/EA021897B1/ru not_active IP Right Cessation
- 2010-11-23 JP JP2012540141A patent/JP5999702B2/ja active Active
- 2010-11-23 EP EP10832344.5A patent/EP2504352B1/en active Active
- 2010-11-23 WO PCT/US2010/057699 patent/WO2011063366A1/en not_active Ceased
- 2010-11-23 AU AU2010321738A patent/AU2010321738B2/en active Active
- 2010-11-23 BR BR112012011787-4A patent/BR112012011787B1/pt active IP Right Grant
- 2010-11-23 NZ NZ599774A patent/NZ599774A/en unknown
- 2010-11-23 CN CN201080060434.0A patent/CN102725305B/zh active Active
- 2010-11-23 KR KR1020127016183A patent/KR101921761B1/ko active Active
- 2010-11-23 MX MX2012005862A patent/MX2012005862A/es active IP Right Grant
-
2012
- 2012-05-08 ZA ZA2012/03330A patent/ZA201203330B/en unknown
- 2012-05-16 US US13/472,914 patent/US8492517B2/en active Active
- 2012-05-23 IL IL219947A patent/IL219947A/en active IP Right Grant
-
2013
- 2013-06-05 US US13/910,422 patent/US8877890B2/en active Active
-
2014
- 2014-10-15 US US14/514,472 patent/US9447148B2/en active Active
-
2016
- 2016-06-07 AU AU2016203785A patent/AU2016203785B2/en active Active
- 2016-09-19 US US15/268,761 patent/US10017539B2/en active Active
-
2018
- 2018-01-17 US US15/873,180 patent/US10711039B2/en active Active
-
2020
- 2020-07-13 US US16/927,347 patent/US11286280B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL219947A0 (en) | Melanocortin-1 receptor-specific cyclic peptides | |
| IL219946A0 (en) | Melanocortin-1 receptor-specific linear peptides | |
| ZA201200128B (en) | Melanocortin receptor-specific peptides | |
| ZA201200112B (en) | Melanocortin receptor-specific peptides | |
| GB0907534D0 (en) | Injection devices | |
| ZA201105852B (en) | Antibiotic peptides | |
| GB0900930D0 (en) | Injection device | |
| EP2408339A4 (en) | COVER MODULE | |
| SI2410869T1 (sl) | Pridobivanje proteinov | |
| GB2505991B (en) | Solvent resistant thermoplastic toughened epoxy | |
| PL2496596T3 (pl) | Peptydy terapeutyczne | |
| EP2440572A4 (en) | SPECIFIC PEPTIDES FROM LACTAM BRIDGE MELANOCORTIN RECEPTORS | |
| GB201012111D0 (en) | Cyclosporin conjugates | |
| EP2480578A4 (en) | MODIFICATION OF POLYPEPTIDE | |
| EP2470190A4 (en) | ECHINOCANDINDERIVATE | |
| ZA201108446B (en) | FViII-DERIVED PEPTIDES | |
| ZA201203722B (en) | Peptide | |
| GB0918321D0 (en) | Cyclic peptide synthesis | |
| GB0905821D0 (en) | Antimicrobial cyclic peptides | |
| GB0921691D0 (en) | Sophorolpid transporter protien | |
| GB2476038B (en) | Contractible bicycle | |
| HK1169123A (en) | Melanocortin receptor-specific peptides | |
| GB0911790D0 (en) | Peptides | |
| IL214496A0 (en) | Short b-defensin-derived peptides | |
| GB0909494D0 (en) | Neuroprotective peptide |